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ABSTRACT OF THESIS

EFFECTS OF REPEATED CUE EXPOSURE ON CANNBIS CRAVING
Craving is a key element of the cannabis withdrawal syndrome that has been associated
with continued use and relapse. Although cue-induced cannabis craving has been established in
single laboratory sessions, procedures to sustain craving over multiple sessions are needed. The
purpose of the present study was to determine if cue-induced craving responses could be elicited in
the same subjects across multiple sessions. It was hypothesized that exposure to cannabis cues
would produce more robust craving responses than exposure to neutral cues and that elicited
craving responses will be sustained across multiple cue exposures. Five experimental cue exposure
sessions (1 neutral and 4 cannabis) were conducted. Craving was assessed with the Marijuana
Craving Questionnaire (MCQ) Short Form, Visual Analog Scale (VAS), Subject-Rated
Physiological Questionnaire, blood pressure, and heart rate. Results revealed significant effects of
initial cannabis cue exposure on VAS craving responses and Subject-Rated Physiological measures
relative to the neutral cue exposure condition. No significant differences were found on MCQ
composite scores or physiological measures. Craving responses following initial cannabis cue
exposure were not maintained across sessions. There is a need for a better understanding of the
factors that contribute to continued drug use despite quit attempts.
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Chapter One: Significance and Background
Cannabis (cannabis sativa, cannabis indica) is the most commonly used illicit drug in the
United States. Results from the 2013 National Survey on Drug Use and Health (NSDUH)
indicated that 6.9 million Americans were dependent on or abusing illicit drugs; cannabis
accounted for almost two-thirds (62%) of that population (4.3 million). Of the 2.8 million people
age 12 or older who used illicit drugs for the first time in 2013, 70.3% reported cannabis as their
first illicit drug of abuse. In 2013, lifetime prevalence rates for cannabis use for persons aged 12
or older were 114.7 million (NSDUH, 2013). In 2013, the number of current cannabis users (past
30 days) age 12 or older was 19.8 million, a number that has been increasing every year since
2007 (Substance Abuse and Mental Health Services Administration (SAMHSA), 2013). In 2013,
2.4 million people age 12 or older used cannabis for the first time, an average 6,600 new cannabis
initiates every day. 1.4 million (58%) of the new cannabis initiates began their use prior to the age
of 18 (SAMHSA, 2013).
For the vast majority of individuals, cannabis use does not escalate over time and does
not interfere with major areas of life functioning. However, approximately 9% of all cannabis
users do in fact become dependent (National Institute on Drug Abuse (NIDA), 2015). That
number increases to 17% among those who start smoking cannabis during their teenage years.
A meta-analysis examining the relationship between cannabis and psychosocial harm
found that cannabis use was negatively correlated with educational attainment (Macleod et al.,
2004). Similar studies found that adolescent cannabis smokers were less likely to finish high
school than their non-smoking peers (Silins et al., 2014). Cannabis use before the age of 25 was
also associated with unemployment, lower income, greater welfare dependence, and lower life
satisfaction (Ferguson & Boden, 2008; Brook et al., 2013).
As with other abused drugs, cannabis use significantly impairs motor coordination and
reaction time. A number of studies have demonstrated that cannabis intoxication impairs motor
vehicle driving similar to alcohol consumption (Groternhermen et al., 2007; Downey et al., 2013).
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The 2011 Drug Abuse Warning Network (DAWN Report) stated that cannabis was a
contributing factor in over 455,000 emergency room visits in the United States, an increase of
52% from 2004. Thirteen percent of those cannabis related emergency department visits were
from individuals age 12-17.
Pharmacokinetics
The cannabis sativa plant contains over 400 different compounds, approximately 60 of
which are considered psychoactive. 9-tetrahydrocannabinol (THC) is considered the compound
that produces the majority of the psychoactive effects associated with cannabis (Gaoni &
Mechoulam, 1964; ElSohly & Slade, 2005; Ashton, 2001). However, other components of
cannabis (e.g. cannabidiol) may also contribute to its psychoactive effects (Borgwardt et al.,
2008).
Smoking is the most common route of administration for 9-THC is smoking. Cannabis
can be hand rolled into cigarettes (joints) or hollowed out cigar papers (blunts), or smoked using
glass pipes (bowls) or water pipes (bongs). A typical cannabis cigarette is estimated to contain
between 500 and 750 mg of 9-THC depending on the potency of the cannabis. This in turn
delivers anywhere from 2.5-20 mg of 9-THC to the smoker. 9-THC absorbed from smoking has
a rapid onset and peak blood levels are typically reached within 10 minutes (McLaren et al.,
2008; Pol et al., 2014). 9-THC blood levels drop to 10% of the peak level within one hour.
However, due to the varying potency among cannabis samples and variability in individual
smoking processes, the amount of cannabis that reaches the lungs during each smoking session
can vary significantly (Doweiko, 2015).
The medicinal properties of cannabis and its components have been the subject of much
research and debate. Currently, there are two FDA approved THC-based medications, dronabinol
(Marinol®) and nabilone (Cesamet®). These orally available medications are used for the
treatment of nausea in patients undergoing cancer chemotherapy and to stimulate appetite in
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patients with AIDS. Other possible uses of THC-based medications include the treatment of
spasticity and neuropathic pain in multiple sclerosis patients, and the treatment of severe
childhood epilepsy and seizure disorders (NIDA, 2015).
Cannabis can also be recreationally administered through oral absorption by either
mixing cannabis with food or brewed as tea. Oral absorption is typically slower than smoked
absorption due to first-pass metabolism (Maykut, 1985). The effects of cannabis are not felt until
30-120 minutes following ingestion. Because a large amount of cannabis is destroyed by the
gastrointestinal tract, oral absorption delivers only 4-12% of available cannabis to the blood
(Ashton, 2001).
Once absorbed, 9-THC is distributed to the various blood rich organs of the body
including the heart and the brain. 9-THC is then slowly absorbed over time to the less blood rich
tissues, such as the body’s fat reserves, where it is stored. Chronic daily abuse of 9-THC results
in large amounts of 9-THC being stored in the body’s fat cells and users may have 9-THC
metabolites in their urine for as long as 30 days (Maykut, 1985; McGilveray, 2005).
The primary site of 9-THC metabolism is in the liver. The half-life of 9-THC depends
on the level of tolerance that has developed in the individual user. In chronic daily abusers, the
half-life of 9-THC can vary anywhere from 24 to 96 hours (Doweiko, 2015). 9-THC is almost
completely metabolized by hepatic cytochrome P450 enzymes to 11-hydroxy-delta-9-THC (the
active metabolite of THC), which is then converted to the inactive metabolite THCCOOH. The
inactive metabolite is then excreted in the urine (Huestis, 2007a).
Mechanism of Action and Neurological Correlates
9-THC imitates the effects of endocannabinoids, naturally occurring ligands in the brain
and the periphery. The five known naturally occurring ligands that bind to the endocannabinoid
receptors are anandamide, virodhamine, N-arachindonoyldopamine, 2-arachidonglycerol, and
noladin ether. All of the naturally occurring ligands are derivatives of arachidonic acid and have
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varying degrees of selectivity for the two known cannabinoid receptors, CB-1 and CB-2 (Munro
et al., 1993; Pertwee, 1998). Endocannabinoid receptors (CB-1 and CB-2) are metabotropic gprotein coupled. Endocannabinoid receptors are located in large amounts throughout the brain,
specifically the cortex, hippocampus, basal ganglia, cerebellum, and spinal cord as well as in the
periphery (Julien et al., 2011).
Endocannabinoids are synthesized by a sudden influx of calcium to the cell. After their
release from cells, the endocannabinoid transporter protein transports the endocannabinoids into
cells where they can be metabolized by fatty acid amide hydrolase (FAAH) (Doweiko, 2015).
CB-1 receptors are located primarily on presynaptic nerve terminals and inhibit calcium influx
and facilitate potassium channels resulting in the inhibition of other neurotransmitter release.
9-THC acts as a partial agonist for the CB-1 and CB-2 receptor sites in the brain and the
periphery. However, unlike the naturally occurring endocannabinoids, 9-THC has a longer halflife, is much more potent, and as a result, is more likely to bind to these receptor sites. There are
large numbers of cannabinoid receptors in the brain. However, 9-THC only activates
approximately 20% of those receptors. According to receptor reserve theory, since there are such
a large number of cannabinoid receptor sites, only a small fraction of these sites need to be
occupied in order to elicit a near maximal effect (Pineda, 1997). In the central nervous system,
9-THC acts on CB-1 receptors located on presynaptic nerve terminals to inhibit the stimulus
evoked release of GABA, NE, and ACh. 9-THC reduces the firing rate of these neurons,
resulting in the calming, sedating effect (Iverson et al., 2009). Although well documented, the
neurobiological mechanism underlying the subjective effects of 9-THC is not well understood.
However, like other drugs of abuse, 9-THC appears to produce its euphoric effects through the
brain’s endogenous opioid neurotransmitter system (Welch, 2005).
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Pharmacodynamics
The psychoactive properties of 9-THC are subjective and vary based on individual
differences and 9-THC potency. Acutely, 9-THC dose dependently produces behavioral effects
including euphoria, analgesia, sensory distortions, relaxation, and decreased anxiety. 50-60% of
cannabis users report experiencing mild anxiety following cannabis administration (Julien et al.,
2011). Drug effects typically occur between 10-30 minutes following administration and last
anywhere from 2-4 hours.
Physiological effects of 9-THC include decreased blood pressure and increased heart
rate due to the vasodilation caused by 9-THC’s actions on CB-1 receptors in blood vessels.
Heart rate is typically increased by 30-50% lasting up to three hours following cannabis use
(Sidney, 2002; Doweiko, 2015; Lile et al., 2010a). The vasodilation can also result in reddening
of the eyes. Cannabis smokers also experience various respiratory problems such as increased
cough, wheezing, acute chest illnesses, and heightened risk of lung infections (Khan et al., 2009).
Consequences of Cannabis Use
A growing body of research has found significant associations between 9-THC and
short-term deficits in cognitive functioning. Short-term cognitive effects of 9-THC include
problems with memory and learning, distorted perception, and difficulty in thinking and problem
solving. The negative effects of cannabis on cognitive functioning can last for days or weeks
following the discontinuation of heavy use (Doweiko, 2015). Additionally, high-potency cannabis
use can result in sensory distortions in some individuals. Chronic cannabis users are at increased
risk for experiencing acute psychotic reactions following use. These psychotic reactions tend to
dissipate after a few hours or days following use and can include delusions and a loss of the sense
of personal identity (Hall, 1998; Johns, 2001; Van Os, 2002).
Previous research determining definitive long-term consequences of cannabis use has
been limited. This is mostly due to poly-substance use and variations in medical and physical
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health history among participants (NIDA, 2015). However, in a recent longitudinal study, over
1,000 individuals were followed from birth to 38 years old. At five waves of data collection
starting at age 18, cannabis use was assessed. Results from this study found that frequent and
persistent adolescent cannabis use was associated with neuropsychological decline, specifically, a
decrease of eight points in average IQ score. Furthermore, following cessation of cannabis use in
adulthood, participants IQ scores did not improve (Meier et al., 2012). Additionally, a review of
48 studies found that chronic cannabis use has been associated with reduced chances of finishing
high school or obtaining a degree (Macleod et al., 2004; Sillins, 2014).
Cannabis Use Disorder
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
has defined Cannabis Use Disorder (CUD) as “a problematic pattern of cannabis use leading to
clinically significant impairment or distress” defined by the presence of at least 2 of 11 listed
criteria occurring within a 12 month period of time. Some of the DSM-5 criteria for CUD
include: craving, failure to fulfill major role obligations, tolerance, and withdrawal.
DSM-5 was the first edition to recognize cannabis withdrawal as diagnostic criteria.
Common withdrawal symptoms include irritability, anxiety, sleep difficulty, restlessness, and
depressed mood. Withdrawal symptoms occur in over 50% of users who discontinue cannabis
use. Withdrawal symptoms usually begin within 48 hours of cessation of use and can last
anywhere from 2-19 days (Julien et al., 2011). Despite the noted withdrawal reactions,
withdrawal symptoms experienced with cannabis are far less intense than those experienced with
other drugs of abuse such as alcohol, benzodiazepines, or opiates. However, withdrawal has been
associated with repeated cannabis use and users report withdrawal symptoms as a trigger for
relapse during quit attempts (Haney et al., 2013a; 2004; Cornelius et al., 2008).
Current Treatment Modalities
Prior to 1994, there were no published controlled research studies focusing on the
treatment of cannabis abuse or dependence (Steinberg et al., 2005). This may be due to previous
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misconceptions that cannabis use did not lead to dependence and that there were no adverse
effects associated with cannabis misuse. We now know that roughly 10% of people who use
cannabis become daily users (McRae et al., 2003). Coffey and colleagues (2002) found that
people who smoke cannabis more than once a week were at a significant risk for dependence. In
the 1990s, the number of people who sought treatment for cannabis dependence more than
doubled. As a result, there was a significant increase in the development of treatment
interventions focusing on cannabis dependence, including both behavioral interventions and
pharmacotherapies.
Behavioral Interventions. Overall, behavioral interventions such as motivational
enhancement therapy (MET) (Copeland et al., 2001), cognitive-behavioral therapy (CBT)
(Stephens et al., 1994), contingency management (CM) (Budney et al., 2000; 2006), and familybased treatments, have reduced cannabis use and increased abstinence relative to delayedtreatment control conditions. The Marijuana Treatment Project (MTP), a large multi-site study,
examined the efficacy of treatment outcomes from three different behavioral interventions with
450 ethnically diverse cannabis dependent adults. Results from the MTP suggest that both a twosession MET treatment and a nine-session treatment incorporating MET, coping skills training,
and case management were significantly more effective in reducing cannabis use than a delayedtreatment control condition. Additionally, cannabis dependence and anxiety symptoms were
reduced following both the two- and nine-session treatment interventions, with the nine-session
intervention showing the greatest improvement (Steinberg et al., 2005). Unfortunately, long-term
success rates of behavioral interventions of CUDs are limited. Across several behavioral
intervention studies, only 10-30% of individuals remain abstinent after one year (Budney et al.,
2007a). Because behavioral therapies have shown limited success, there is a recognized need for
research on the development of pharmacotherapies to assist treatment seekers with the initiation
and maintenance of abstinence.
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Pharmacotherapies. Currently, there are no FDA approved medications for the
treatment of cannabis dependence or for the management of cannabis withdrawal or craving.
Research studies and subsequent pharmacotherapies have been developed for the treatment of
alcohol, nicotine, and opioid dependence. However, until recently, research efforts focusing on
pharmacotherapies for cannabis use disorders have been minimal by comparison. Laboratory
studies have been designed to examine the efficacy of several medications in the attenuation of
cannabis withdrawal symptoms, subjective and reinforcing effects, and to prevent relapse.
Dronabinol. Dronabinol is chemically synthesized 9-THC and acts as a partial agonist.
Dronabinol is available under the trade name Marinol® in 2.5, 5, or 10 mg capsules for oral
administration. Marinol® is used for stimulating appetite and preventing weight loss in patients
with AIDS and treating nausea and vomiting caused by cancer chemotherapy. For these reasons,
dronabinol has been used in laboratory settings as a potential medication adjunct for cannabis
relapse and withdrawal.
Laboratory studies have shown that varying doses of dronabinol (10, 20, and 30 mg)
administered multiple times daily attenuate withdrawal symptoms typically associated with CUDs
(Haney et al., 2004; 2008; Budney et al., 2007b). In a similar study by Vandrey and colleagues
(2013), daily cannabis smokers were given oral doses of dronabinol (0, 30, 60, and 120 mg) for
five days. On the fifth day of dronabinol maintenance, subjects smoked five puffs of a cannabis
cigarette. Results showed that dronabinol dose-dependently decreased cannabis withdrawal.
Similar results were demonstrated by Levin and colleagues (2011). In this 12-week randomized
placebo-controlled trial, 156 cannabis dependent adults were administered 20 mg twice daily of
dronabinol or placebo. Results showed that dronabinol significantly improved treatment retention
and withdrawal symptoms relative to placebo. However, dronabinol did not significantly effect
post-treatment cannabis use or abstinence rates.
Dronabinol has also been shown to attenuate the subjective effects of smoked cannabis.
In one such study by Hart and colleagues, (2002) healthy cannabis dependent individuals were
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given oral doses of dronabinol (either 0, 10, or 20 mg) for three days followed by three days of
placebo maintenance. Relative to placebo, dronabinol maintenance significantly decreased
subjective reporting of “Good Drug Effect” and “High” following smoked cannabis
administration (1.8% 9-THC). Other studies however, have failed to demonstrate a reduction in
subject effects of smoked cannabis following dronabinol administration (Vandrey, 2013).
Nabilone. Nabilone is a synthetic analog of THC that acts as a CB-1 agonist. Nabilone is
currently used for the control of nausea and vomiting caused by chemotherapy. Drug
discrimination studies show that nabilone substituted for dronabinol (Lile et al., 2010b). For these
reasons, nabilone has been used in laboratory settings as a potential medication adjunct for
cannabis relapse and withdrawal. In one such study by Haney and colleagues (2013b), healthy
cannabis dependent individuals were given oral doses of nabilone (0, 6, and 8 mg/day) under both
placebo and active cannabis self-administration conditions. Both active nabilone conditions
attenuated cannabis self-administration and decreased withdrawal symptoms.
Naltrexone. Naltrexone acts as an opioid antagonist at all three opioid receptors, with the
highest affinity for the μ opioid receptor. Preclinical research has demonstrated that naltrexone
blocks the effects of cannabis (see Weinstein & Gorelick, 2011 for review). In cannabis users,
results of naltrexone use have been mixed. Previous human studies have demonstrated that acute
pretreatment of naltrexone actually increased the positive subjective effects of cannabis (Cooper
& Haney, 2010). Other studies have shown that naltrexone maintenance decreases cannabis selfadministration and subjective VAS ratings of “Good Effect” (Haney et al., 2015).
Rimonabant. Rimonabant acts as a selective, potent, and orally active CB-1 receptor
antagonist. Rimonabant was developed as a CB-1 antagonist and proved successful at blocking
the effects of 9-THC in pre-clinical studies (Tseng & Craft, 2004). Rimonabant has been
approved for use in Europe and other countries; however it has not been approved in the United
States. Acute administration of rimonabant has been shown to reduce subjective drug effects in
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cannabis dependent individuals (Huestis et al., 2001). In a double-blind, randomized trial,
subjects received either 0, 40, or 90 mg of rimonabant. During two laboratory sessions, subjects
smoked either active or placebo cannabis. Both active rimonabant conditions attenuated the acute
physiological effects of smoked cannabis and acutely attenuated subjective responses (Huestis et
al., 2007b).
Nabiximols. Nabiximols is a cannabinoid receptor agonist and the first cannabis-based
medication licensed in the UK. It is currently approved for muscle spasticity related to multiple
sclerosis. Nabiximols is an oromucosal spray containing 9-THC and cannabidiol. Because of its
route of administration, nabiximols has a more predictable pharmacokinetic profile than oral THC
and has a lower abuse potential than dronabinol (Schoedel et al. 2011). In a double-blind,
randomized, placebo-controlled clinical inpatient trial, subjects were given either active
nabiximols (maximum daily dose, 86.4 mg of Δ9-tetrahydrocannabinol and 80 mg of
cannabidiol) or placebo. Acutely, nabiximols significantly reduced cannabis withdrawal relative
to placebo. Additionally, nabiximols improved patient retention in treatment (Allsop et al., 2014).
Other possible pharmacotherapy agents investigated have included buspirone, lithium,
lofexidine, N-acetyl cycteine (NAC), and gabapentin (see Vandrey & Haney, 2009 for review;
see Balter et al., 2014 for review). NAC and gabapentin in particular, have been tested in
randomized control trials. In an 8-week double-blind randomized placebo-controlled trial, 116
cannabis-dependent adolescents received either 1200 mg of NAC or placebo. Results showed that
adolescents in the NAC treatment condition had more than twice the odds relative to placebo of
having a THC negative urine toxicology screen during treatment (Gray et al., 2012). In a 12week double-blind randomized placebo-controlled trial, cannabis-dependent adults received
either 1200 mg of gabapentin or placebo. Results showed that gabapentin significantly reduced
cannabis use and cannabis related withdrawal symptoms relative to placebo (Mason et al., 2012).
There is a need for increased research on the development of more effective
pharmacotherapies for CUDs. Although numerous possible pharmacotherapy agents have been
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studied, none have been approved by the FDA for the treatment of CUDs. Research has shown
that a combination of pharmacotherapy and behavioral interventions result in greater treatment
improvement outcomes relative to either intervention alone (Vandrey & Haney 2009).
Craving and Cue Exposure
It is generally understood that an interaction between various biological, psychological,
and social factors contribute to addiction and relapse. One of the primary goals of drug treatment
programs is for the individual to achieve and maintain abstinence from drug use. Drug craving is
an intense, emotional, and physical experience resulting in an impulse to use drugs. Drug craving
can interfere with an individual’s ability to maintain abstinence after quit attempts. Craving can
elicit physiological responses similar to those associated with substance abuse including anxiety,
increased heart rate, and sweaty palms. Craving for cannabis is a key element of the withdrawal
syndrome that has been characterized in abstinent individuals with a history of chronic use.
Craving has been associated with continued substance use and relapse during quit attempts in the
natural environment, but not causally linked in a laboratory setting (Drummond et al., 2000;
Weiss, 2005; Carter & Tiffany, 1999; Childress et al., 1993).
Exposure to drug cues (e.g., handling drug paraphernalia, audio and visual drug-related
stimuli) induces robust subjective reports of craving. Cue-induced craving for cocaine (Robbins
et al., 1992), opioids (Hyman et al., 2007), alcohol (Fox et al., 2007), and tobacco (Ferguson &
Shiffman, 2009) has been established in laboratory settings. Previous research has also
demonstrated increased subjective craving responses in cannabis dependent individuals following
exposure to cannabis cues.
In one such study, daily cannabis users and a control group of cannabis-naïve individuals
were exposed to both neutral cues and cannabis cues in a single laboratory session. During the
neutral phase, subjects were exposed to a variety of neutral objects (i.e., pencils, eraser, ruler).
Subjects were instructed to handle and smell the objects while viewing a videotape of nature
scenes. After a brief rest period, the cannabis phase began. During this phase, subjects were
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exposed to a variety of cannabis-related paraphernalia (i.e., bong, pipe, papers). Subjects were
instructed to handle and smell the objects while viewing a videotape of young adults smoking.
Mood and subjective craving effects were measured at baseline and following both the neutral
and cannabis phases. Responses on the craving measures increased from baseline following
cannabis cues relative to neutral cues, but only for the cannabis dependent group (Lundahl &
Johanson, 2011). Similar single session studies examining cue reactivity in cannabis smokers also
found greater subjective craving responses during the presentation of cannabis cues relative to
neutral cues (Nickerson et al., 2011, Gray et al., 2008; 2011; Bordnick et al., 2009; McRae-Clark
et al., 2011). Skin conductance also increased during the presentation of cannabis cues relative to
neutral cues (Gray et al., 2008; 2011; Wolfling et al., 2008).
Successful use of a cue-induced craving within-subjects design has been demonstrated in
a recent study by Lundhal and Greenwald (2015). In this study, 14 cannabis dependent
individuals were pretreated with placebo, 10, or 20 mg of oral THC. Following THC
administration, subjects were exposed to a 10 minute neutral cue exposure followed by a 10
minute cannabis cue exposure. Results showed significant increases on the Marijuana Craving
Questionnaire (MCQ) compulsivity scores following cannabis cues relative to neutral cues.
Additionally, significant increases were found on Visual Analog Scale (VAS) items “desire to use
marijuana,” “urge to smoke marijuana,” and “craving for marijuana.”
Behavioral Models of Drug Use and Craving
Behavioral models of substance abuse are primarily influenced by B. F. Skinner’s operant
learning theory and Ivan Pavlov’s classical conditioning theory. Operant conditioning models are
based on the notion that drug use and addiction are maintained through general learning and
reinforcement principles. According to this model, drug-taking behaviors are initiated and
maintained because of the positive reinforcing effects of drug use. Following cessation of drug
use, individuals are likely to experience increased discomfort associated with craving and
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withdrawal. According to the operant learning model, relapse to drug use can be understood as a
means of reducing the negative discomfort associated with craving and withdrawal.
Ivan Pavlov’s classical conditioning model is useful in understanding the processes
involved in cue-induced craving. In its most basic form, a neutral stimulus (NS) is paired with an
unconditioned stimulus (US) that innately elicits a central nervous system physiological response
(UR). When administered alone, the NS does not elicit the physiological response. However,
through repeated pairings of the NS and US, the NS becomes a conditioned stimulus (CS)
eliciting a conditioned response (CR) (Seigel & Ramos, 2002). Through the process of classical
conditioning, stimuli that have been previously associated with drug taking behavior (e.g., drug
paraphernalia) act as conditioned stimuli in absence of the actual drug of abuse. The classical
conditioning model demonstrates how through repeated pairings, drug cues serve as
discriminative stimuli (paraphernalia, environment, viewing drug use, etc.) and elicit
neurobiological changes resulting in drug craving symptoms (see Carter & Tiffany, 1999 for
review).
Cannabis dependence is a chronically relapsing condition (Koob, 2006; Taylor et al.,
2009). Craving is a key element in relapse and can occur following periods of abstinence. In cue
exposure treatment models, a client is presented with drug cues; however, the client is prevented
from taking drugs. The theory is that this extinction procedure, overtime, can lead to breaking the
classical conditioning pairing resulting in decreases in reactivity to drug cues. Results, however,
have been mixed. Preclinical research has demonstrated that cue exposure models can be used to
attenuate drug-seeking behavior (Buffalari et al., 2013; Kearns et al., 2012). However, other
preclinical studies have not shown reduction in drug-seeking behavior (Crombag et al., 2002).
Similarly, in humans, the results of cue exposure therapy (CET) are mixed. Some CET studies
show promise as an adjunct treatment (Lee et al., 2007; Santa Ana et al., 2015), while others
actually show increased relapse rates compared to placebo (Marissen et al., 2006).
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Craving as a Construct
Although previous literature highlighted the importance of cue-induced craving, the
specific construct of craving and its validity as a laboratory measure have been widely debated.
One of the major problems when exploring craving as a construct is variation in methodology
used. Drug craving can be measured through self-report questionnaires, physiological indices
(i.e., blood pressure, heart rate), or behavioral paradigms (i.e., self-administration). As a result,
standard methods of measuring subjective craving in laboratory settings have yet to be
established (Marlatt 1990, Tiffany et al., 2000). Another issue arises when discussing the
variations in self-reported craving. Specifically, researchers differ as to whether craving should be
assessed across a broad continuum (i.e., Visual Analog Scale) or with a more limited
characterization (i.e., Marijuana Craving Questionnaire). As a result, construct validity has been
almost impossible to establish (Sayette, 2000).
The operational definitions notwithstanding, exposure to drug cues have been shown to
increase subjective reports of craving across all drugs of abuse in laboratory settings. There is a
need for a better understanding of the factors that contribute to continued drug use despite quit
attempts in order to develop models and procedures for the evaluation of behavioral and
pharmacological therapies for treatment. The disproportionate amount of CUDs and new initiates
relative to treatment seekers highlights the importance of developing new treatment modalities for
cannabis use disorders.

Copyright © Jessica S. Fogel 2015
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Chapter Two: Purpose of Project
The purpose of the present protocol was to test whether a cue reactivity procedure could
elicit a craving response within-subjects in a laboratory setting and to see whether those craving
responses could be sustained across multiple sessions. In general, previous cue reactivity
paradigms have used group designs and have not reported on the test-retest reliability of the
craving response to drug cues. Considering the strength of within-subjects designs in medication
development research, an important step would be to demonstrate that cue-induced craving
responses of similar magnitude can be elicited in the same subjects across multiple sessions.
Craving can be an important contributor to relapse following quit attempts. Subjective
drug craving is an important component of the addiction process that is not captured through
other studied laboratory models of addiction such as pharmacological selectivity (Lile et al, 2011;
2012), self-administration (Haney et al., 1997), or attentional bias (Field & Cox, 2008). A better
understanding of the craving processes is important in helping individuals maintain sobriety
following quit attempts.
The present study focused on the effects of cue exposure on subjective craving. Drug
cravings are intense subjective experiences that can be triggered by internal stimuli or external
drug cues. Because of the subjective nature of craving responses, the present study examined
individual subjective responses to cue-induced craving.

Copyright © Jessica S. Fogel 2015
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Chapter Three: Hypothesis
Behavioral
Exposure to cannabis cues will produce more robust craving responses than exposure to
neutral cues. Following neutral cue presentation, daily cannabis smokers will report no change on
the subject-rated craving responses from baseline. Changes on other VAS items will not be
affected. Following cannabis cue presentation, daily cannabis smokers will report an increase on
subject-rated craving responses from baseline. It was also hypothesized that subject rated craving
responses to cannabis cues would be sustained across multiple cue exposure sessions.
Physiological
Consistent with previous studies, no changes from baseline are anticipated following the
neutral and cannabis cue presentations on either the subject rated physiological questionnaires or
cardiovascular physiological measures.

Copyright © Jessica S. Fogel 2015
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Chapter 4: Method
The proposed experiment and informed consent document have been approved by the
Institutional Review Board of the University of Kentucky Medical Center.
Subject Recruitment
Subjects were recruited through local community internet, newspaper and radio
advertisements, bulletin board postings, and word-of-mouth. Inclusion in the study was
contingent on daily cannabis use. Subjects needed to be between the ages of 18-50 and in good
health except for their drug use. Tactile, auditory, or visual conditions that would impact
perception of drug cues, history of serious physical or psychiatric disease, and current use of
psychiatric medications were exclusionary. Additionally, subjects who wished to seek treatment
for their drug use were also excluded from the study. During the recruitment phase, subjects were
not informed of the specific inclusion/exclusion criteria noted above.
Subjects made initial contact with the research facility either by phone or through the
internet (http://rrf.research.uky.edu/). During this initial contact, a brief screening regarding the
inclusion/exclusion criteria was conducted. Prospective subjects were then provided with
additional details of the study and were invited to begin the screening component. All potential
subjects who were identified using the recruitment methods noted above received oral and written
descriptions of the study prior to providing written consent.
Payment
Subjects were paid $20 for completing the screening packet. Subjects were paid $20 for a
practice session and $20 for each of the five subsequent experimental sessions. Subjects received
an additional $20 completion allowance for each of the six sessions (1 practice + 5 experimental)
if they completed the entire experiment. Subjects who were terminated for medical reasons
received all of the money they earned through their termination date as well as the $20
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completion allowance. The maximum amount of money a subject could receive was $260 ($240
for study participation + $20 for screening).
Screening
Initial in-person screenings lasted between one and three hours and were conducted at the
UK Residential Research Facility (RRF). During the initial screening, subjects were given the
IRB-approved informed consent document to read and sign. Subjects were advised of the
voluntary nature of participation and of their right to withdraw from the project at any time.
Subjects were also advised of aspects of the study protocol including potential study risks and
benefits, payment, confidentiality of information, and rights as a research participant. Subjects
were required to abstain from cannabis use on the day of, and from alcohol use 12 hours prior to
the experimental session. Repeated alcohol and drug violations resulted in dismissal from study
participation. Study investigators addressed any questions or concerns the subject had prior to
obtaining consent. Subjects were informed that staff members were available at any point during
the study to answer questions or explain study procedures.
Once the subject agreed to participate in the present protocol, a breathalyzer and urine
toxicology screen was conducted. Breath samples positive for alcohol or a urine sample positive
for drugs of abuse (other than cannabis) precluded the subject from participation in screening that
day. Subjects were also asked to provide an expired air sample that was tested for the presence of
carbon monoxide (CO).
Subjects then completed computerized screening assessments which included
information about: demographics, family medical history, past and present medical and mental
health history, past and present drug and cannabis use history, and the Structured Clinical
Interview for DSM-IV (SCID). Subjects then filled out a Cannabis Use Calendar (Appendix A).
This was followed by an assessment of vital statistics including heart rate, blood pressure, and
weight. Subjects were paid for their participation in the initial screening.
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Of note, screening procedures for behavioral pharmacology studies conducted at the RRF
typically include a physical health screening (blood/urine analysis and ECG) with results
reviewed by a study physician. However, because of the minimal risk associated with the protocol
and because drugs were not administered, these procedures were not included.
Experimental Procedures
Experimental procedures were conducted on an outpatient basis at the RRF. Upon arrival,
subjects relinquished their keys, watches, and mobile phones, which were stored securely until
the end of the session. A field sobriety test was then conducted to ensure that subjects were not
intoxicated prior to session initiation. A breathalyzer and urine toxicology screen were conducted.
Breath samples positive for alcohol or a urine sample positive for drugs of abuse (other than
cannabis) precluded the subject from participation in the experimental session. Urine samples
from female subjects that were positive for pregnancy resulted in dismissal from the study.
Subjects then completed the Sign-In Questionnaire that assessed past 24-hour nicotine,
alcohol, caffeine, and cannabis use, medication use since their last session, and any changes in
their normal routine. The Sign-In Questionnaire can be found in Appendix B. Subjects who
smoked cigarettes were then allowed to smoke a single cigarette before the session began.
Subjects were not allowed to smoke again until the end of the experimental session.
The study consisted of one practice and five experimental (1 neutral + 4 cannabis cue)
sessions. Experimental session rooms at the RRF were equipped with Macintosh computers
programmed to present the sessions tasks in a prearranged sequence. Data were stored in files
coded for participant identity protection. Files were backed up at the end of each session.
Practice session. Subjects completed a practice session prior to beginning experimental
sessions to familiarize them with the behavioral tasks and timeline of the experimental protocol
described below. During these practice sessions, subjects were exposed to the neutral, but not
cannabis, cue condition.
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Experimental sessions. Subjects completed five experimental sessions after successfully
completing the practice session. Experimental sessions included behavioral tasks as well as either
a cannabis or neutral cue presentation. The order of cue presentations was randomly assigned.
The timeline for the experimental sessions is shown in Table 4.1 below. The complete Study Run
Sheet is shown in Appendix C.
Table 4.1. Daily Schedule Timeline
Time

Procedure

-30

Check in Procedures (BAC, CO, urine toxicology, weight, Sign-In
Questionnaire)

0

MCQ, VAS, HR, BP

5

Cue Exposure, Physiological Questionnaire, MCQ, VAS, HR, BP

30

MCQ, VAS, HR, BP

60

MCQ, VAS, HR, BP
Check out Procedures

Physiological measures assessed during the four noted time points included heart rate and
blood pressure. Subjective responses were assessed during the four noted time points with the
Marijuana Craving Questionnaire (MCQ) Short Form and the Visual Analog Scale (VAS).
Immediately following the cue presentation, subjects filled out an 11-item Subject-Rated
Physiological Questionnaire that was locally developed.
Physiological Response
Heart rate and blood pressure were measured using a Dinamap digital monitor (Critikon,
Pro 200, Tampa, FL). Vital signs were measured during the practice and experimental sessions at
baseline, immediately following the cue presentation, 30 minutes following baseline, and 60
minutes following baseline.
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Subject-Rated Drug-Effect Questionnaires
Marijuana Craving Questionnaire (MCQ) Short Form. The Marijuana Craving
Questionnaire (MCQ) was developed and validated as a 47-item self-report assessment
(Heishman et al., 2001). In 2009, a short form of the questionnaire was developed as a 12-item
assessment divided into four subscales: compulsivity, emotionality, expectancy, and
purposefulness. There are three MCQ items in each of the four subscales. Subjects were shown
statements regarding cannabis use and anticipated effects on a computer screen and were asked to
indicate their answer by using a computer mouse to select one of 7 options ranging from
“strongly disagree” (scored as 1) to “strongly agree” (scored as 7). Composite scores are
produced for each subscale, with a maximum score of 21 on each subscale. The MCQ short form
is reprinted in Appendix D.
Visual Analog Scales (VAS). Subjects were asked to rate themselves across nine
different dimensions (e.g. shaky or jittery, restless) and five self-report craving items by placing a
mark on a 100-unit line with the left endpoint of the continuum labeled “Not at all” and the right
endpoint labeled “Extremely.” Each item was scored by how many millimeters the participant
placed the marker from the left end of the scale indicating “Not at all” (scored as 0) to the right
end of the scale indicating “Extremely” (scored as 100). The maximum possible score for any of
the VAS items was 100. Due to a possible ceiling effect (i.e., craving levels are elevated and
therefore insensitive to the experimental manipulation), subjects who scored greater than or equal
to 50 out of 100 on the VAS “Cannabis craving” item during the neutral session were not
included in the present analysis. VAS items are found in Appendix E.
Subject-Rated Physiological Questionnaire. The Subject-Rated Physiological
Questionnaire was administered one time only immediately following the cue exposure. Subjects
were asked to rate how strongly they experienced 11 different physiological symptoms (e.g. faster
heart rate, rapid breathing). Subjects were asked rate how they were thinking or feeling during the
time they were handling the objects during the cue exposure. Items were rated on a five-point
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scale ranging from “Not at all” (scored as 0) to “All of the time” (scored as 4). The Subject-Rated
Physiological Questionnaire is reprinted in Appendix F.
Cue Exposure Conditions
Cue exposure conditions lasted eight minutes and included a three-minute tactile cue, a
one-minute imagery prompt, and a four-minute visual cue. For the tactile cue, an opaque pitcher
containing either neutral or cannabis physical cues was placed on the participant’s desk at the
beginning of each of the cue exposure sessions. Following each cue presentation, subjects
completed the Subject-Rated Physiological Questionnaire, MCQ, and VAS. In addition, heart rate
and blood pressure were taken.
Neutral cue exposure. Neutral cue exposure instructions were displayed on the computer
screen. The neutral cue exposure timeline was as follows:

Time (seconds)

Instructions

0

Please remove the cover and look at the objects.

60

Please pick up and hold the objects.

180

Please place the objects back on the tray and replace the cover.

210

Please think of a recent time and place where you were most relaxed.

240

Video starts: (run time: 4 minutes)

480

Video ends: Subject-Rated Physiological Questionnaire, MCQ, VAS, HR, BP

Objects presented during the neutral cue exposure included a variety of school supplies
(e.g. pencils, erasers, a ruler). The video presented during the neutral cue was of various nature
scenes (e.g. waterfalls, mountains). At the conclusion of the video the assessments began.
Cannabis cue exposure. Cannabis cue exposure instructions were displayed on the
computer screen. The cannabis cue exposure timeline was as follows:
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Time (seconds)

Instructions

0

Please remove the cover and look at the objects.

60

Please pick up and hold the objects.

180

Please place the objects back on the tray and replace the cover.

210

Please think of a recent time and place when you enjoyed smoking cannabis.

240

Video starts: (run time: 4 minutes)

480

Video ends: Subject-Rated Physiological Questionnaire, MCQ, VAS, HR, BP

Objects presented during the cannabis cue exposure were a variety of cannabis
paraphernalia (e.g., a rolled joint containing an inactive cannabis substitute, pipe, rolling papers).
The video presented during the cannabis cue exposure was of young adults smoking (e.g.,
preparing to smoke, smoking in several different settings). At the conclusion of the video the
assessments began.

Copyright © Jessica S. Fogel 2015

23

Chapter Five: Data Analysis
Statistical analyses were used to investigate the effects of cue exposure on subjective and
physiological assessments. For all statistical analyses, effects with p ≤ .05 were considered
significant. Daily peak effects following cue exposure were analyzed using one-factor, repeatedmeasures ANOVA with cue exposure session (cannabis 1, cannabis 2, cannabis 3, cannabis 4, and
neutral) as factors. If a main effect of session type attained statistical significance, planned
comparisons of active drug cue exposure session days to the neutral cue exposure session were
conducted.

Copyright © Jessica S. Fogel 2015
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Chapter Six: Results
Subjects
Eleven (5M, 6F) non-treatment-seeking daily cannabis users were included in the present
analysis. Ages ranged from 19 to 29 years. Seven of the subjects were White; four of the subjects
were Black. Subjects had been smoking cannabis for an average of six years with a range of 2
years to 13 years of use. Table 6.1 presents the age, weight, race, self-reported daily caffeine and
cigarette use, weekly alcohol and cannabis use, and number of years using cannabis for the eleven
subjects.
Twenty-two subjects reported to the RRF for the initial screening procedures. Of the 22,
four were excluded because they did not meet the cannabis use criteria (smoked less than 25 days
per month), two were excluded because of repeated drug and alcohol abstinence violations, one
was excluded because of a positive PTSD SCID diagnosis, and one voluntarily discontinued her
involvement in the study. Of the 14 remaining subjects, three were excluded because of high
baseline levels of VAS cannabis craving scores. Subject demographic information is presented in
Table 6.1.
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Table 6.1. Subject demographic information.
Sex

N = 5 M, 6 F

Race/Ethnicity

N = 7 White, 4 Black
Mean (SD)

Age

21.13 (3.52)

Weight (lbs)

154.65 (25.41)

Marijuana (days/month)

27 (1.68)

Number of years used marijuana

6 (3.79)

Alcohol (days/week)

1.67 (1.31)

Cigarettes (per day)

2.1 (3.38)

Caffeine (mg/day)

140.8 (83.83)

Physiological response. No significant differences were found on physiological
measures (i.e., BP and heart rate) following cannabis cue conditions relative to the neutral cue
condition. F-values are shown in Table 6.2.
Marijuana Craving Questionnaire. No significant cue exposure effects were found for
any of the MCQ composite scores. F-values are shown in Table 6.2.
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Table 6.2. F-values from peak-effect analysis for subject-rated drug-effects measures and
physiological indices as compared to the neutral session day (Bold indicates a significant Fvalue).

Outcome Measures

F-Values

Physiological Response
Heart Rate
Blood Pressure
Diastolic
Systolic

2.33 (p = 0.07)
2.44 (p = 0.06)
0.95

Subject-Rated Drug Effect Questionnaires
Marijuana Craving Questionnaire (MCQ)
Composite Scores
Compulsivity
Emotionality
Expectancy
Purposefulness

0.57
2.08
0.17
1.28

Visual Analog Scale (VAS)
I Feel…
Sedated
Stimulated
Nauseated
Shaky or Jittery
Restless
Dizzy
Difficulty Concentrating
Anxious
Nervous
I Have a Craving For…
Alcohol
Tobacco
Marijuana
Cocaine
Opiates

1.49
1.23
0.76
0.89
0.92
1.00
0.74
1.19
0.54
0.68
2.30
2.92 (p < 0.05)
---
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Table 6.2 (continued). F-values from peak-effect analysis for subject-rated drug-effects
measures and physiological indices as compared to the neutral session day (Bold indicates a
significant F-value).

Subject-Rated Physiological Questionnaire
Faster heart rate
Rapid breathing
Sweating hands
Heavy feeling in stomach
Loud pounding heart
Tensed muscles
Cold hands
Feeling flushed or hot
Salivating more
Trembling
Dry mouth

4.04 (p < 0.01)
1.00
1.00
-0.73
0.43
1.35
1.00
1.97
---

Visual Analog Scale. A one-factor, repeated-measures ANOVA revealed a significant
effect of cue exposure condition on subjective craving response on the VAS item “I have a
craving for Marijuana” (F4,40 = 2.92, p < 0.05). Contrasts indicated that the mean score for
subjects in the initial cannabis cue condition (M = 20.09, SD = 20.26) was significantly higher
than the mean score for subjects in the neutral cue condition (M = 9.18, SD = 11.46). Results
showed subjects experienced greater subjective cannabis craving responses following the Day 1
cannabis cue exposure compared to neutral cue exposure. No significant differences were found
on subsequent cannabis cue conditions (i.e., day 2-4) relative to the neutral cue condition. Results
are shown in Figure 6.1. F-values are shown in Table 6.2.
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Figure 6.1.
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Subject-Rated Physiological Questionnaire. A one-factor, repeated-measures ANOVA
revealed a significant effect of cue exposure condition on subject-rated physiological response
during the tactile cue presentation. Specifically, subjects reported significant increases in
subjective awareness of a faster heart rate (F4,40 = 4.04, p < 0.01) following the initial cannabis
cue condition (M = 1.45, SD = 0.52) as compared to the neutral cue condition (M = 1.00, SD =
1.00). No significant differences were found on the Subject-Rated Physiological Questionnaire
responses on subsequent cannabis cue conditions (i.e., day 2-4) relative to the neutral cue
condition. Results are shown in Figure 6.2. F-values are shown in Table 6.2.
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Chapter Seven: Conclusion
The purpose of the present protocol was to test whether a cue reactivity procedure could
elicit craving responses in a within-subjects laboratory setting. Additionally, the protocol aimed
to see whether craving responses could be sustained across multiple experimental laboratory
sessions.
It was hypothesized that exposure to cannabis cues would produce more robust craving
responses than exposure to neutral cues in daily cannabis smokers in a within-subjects design. It
was also hypothesized that subject-rated craving responses to cannabis cues would be sustained
across multiple cannabis cue exposure sessions.
Results showed that initial cannabis cue exposure significantly increased subjective
responses of craving compared with neutral cue exposure. These data are in agreement with
previous research demonstrating increased subjective ratings of craving following drug cue
exposure (Lundahl et al., 2011; Nickerson et al., 2011; Gray et al., 2008, 2011; Bordnick et al.,
2009; McRae-Clark et al., 2011). Contrary to the hypothesis, the increased craving responses
following cannabis cue exposure were not maintained across sessions (i.e., days 2-4). In recent
study by Lundahl and Greenwald (2015), repeated cue exposures successfully elicited increased
craving responses across multiple session days. A main difference between these studies is that
Lundahl and Greenwald (2015) administered varying doses of oral THC prior to cue exposure,
whereas this study did not. The Lundahl analysis focused on the effects of differential oral THC
pretreatment on cannabis craving across multiple sessions. In contrast, the present study focused
on the effects of session day on craving responses.
No significant differences were found on physiological measures (i.e., blood pressure and
heart rate) following cannabis cue conditions relative to the neutral cue condition. The failure to
detect changes in heart rate and blood pressure was expected. These data are consistent with
previous findings (Lundahl et al., 2011; Gray et al., 2008; Nickerson et al., 2011) that did not
detect cardiovascular physiological changes following cannabis cues relative to neutral cues.
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Initial cannabis cue exposure did however significantly increased subject-rated
physiological response of “Faster Heartbeat.” Subjects reported increased awareness of a faster
heartbeat during the time they were handling the cannabis cue objects relative to the neutral cue
objects. This outcome is consistent with classical conditioning theory. According to the classical
conditioning model, conditioned stimuli such as drug cues will, over time, elicit drug-related
physiological responses because of their repeated pairings with drug use.
Despite this subjective report of increased heartbeat, there were no actual increases in
physiological measures of heart rate following cannabis cue exposure. One possible explanation
could be that subjects detected a slight increase in heart rate that was not statistically significant.
A second possible explanation could be that the physiological measure of heart rate was done at
the end of the time point following the completion of the Subject-Rated Physiological
Questionnaire, MCQ, and VAS. This one to two minute time lapse between the Subject-Rated
Physiological Questionnaire and the physiological assessment might account for why the
physiological change in heart rate was not detected. Future studies might seek to assess
physiological measures closer to the completion of the cue exposure.
No significant differences were found on type of cue exposure session for any of the four
MCQ subscales. The failure to observe cue-induced changes in MCQ ratings is inconsistent with
previous studies. Previous research has demonstrated an increase in subjective ratings on the
MCQ following active cannabis cue exposure (Lundahl et al., 2011; 2015; Gray et al., 2008;
McRae-Clark et al., 2011). One possible explanation for this discrepancy could be due to
differences of the cannabis cues used. For example, Gray and colleagues (2008) had participants
“flick” a lighter during the tactile cue presentation, allowing for a more active involvement with
the cannabis cues. Previous studies have also included olfactory cues and asked participants to
smell a cannabis cigarette during cannabis cue exposure (Gray et al., 2008; Lundahl et al., 2011).
These differences may have led to differences in subject-rated impact and incentive salience
attributed to the cannabis cues.
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Several limitations should be considered. At no point during the study were subjects
given access to smoke cannabis. Cannabis administration following cue exposure might have
increased the salience of the cannabis cues. This in turn might have resulted in greater subjective
craving responses following cannabis cue exposure. A second limitation of this study is the
repetitive nature of the cannabis cue conditions. Previous research has focused on craving
responses in single laboratory sessions. To our knowledge, this is the first study to examine the
effects of multiple cue exposure sessions on cannabis craving. Participants in the present study
were shown the same objects and video clip during each of the four cannabis cue exposure
conditions. Subjects could have become sensitized to the repeated cannabis cue objects over time.
This could explain the decrease in craving responses following the initial cannabis cue condition
(i.e., days 2-4).
Another limitation was the lack of variability of cannabis paraphernalia during the
cannabis cue exposure. Cannabis paraphernalia presented during the cannabis cue exposure
condition consisted of a rolled joint, pipe, lighter, and rolling papers. The video clip involved
someone rolling a joint and someone smoking a pipe. Since type of smoking preference is so
varied (pipe, water pipe, blunt, joint, etc.), capturing a broader array of smoking preferences may
tap into a more specific individualized cue responses.
Another possible limitation was the characteristics of the subjects enrolled in the study.
Subjects recruited for the study were high functioning. The majority had full-time jobs, some had
children, and some were enrolled as full time students. The majority of the subjects enrolled
incorporated cannabis smoking into their otherwise full, daily routine. Cannabis cue exposure
might differentially impact subjects who smoke cannabis multiple times throughout the day
compared with subjects who, for example, smoke cannabis once a day or before they go to sleep.
Previous research has shown differences in subjective responses to Δ9-THC between frequent and
infrequent cannabis users (Kirk and De Wit, 1999). Although subjects in the present study were
required to smoke cannabis at least 25 days per month, subjects varied in the daily amount of
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cannabis smoked, ranging from 1 to 6 times per day. Additionally, subjects in the present study
reported lifetime cannabis use ranging from 2 years to 13 years. Future research should explore
both daily and lifetime differences in cannabis use patterns as it relates to craving and cue
exposure.
Future research should use more salient cannabis cues during the active drug cue
exposure. For example, using a cannabis that is filled with actual cannabis may increase craving
responses since it would have a more realistic look, feel, and smell than using a cannabis-like
substitute. The closer laboratory cue exposure conditions can get to real world drug taking
behavior, the greater likelihood craving responses will be increased. Additionally, future cue
exposure studies should look to individualize cue exposure conditions and try to make laboratory
conditions mimic subjects’ real world drug taking situations as closely as possible.
There is limited research in the field directly linking cannabis craving with drug taking
behavior. Craving has been associated with continued substance use and relapse during quit
attempts in the natural environment. The present study was designed to be the first of a larger
three-phase study. The purpose of the initial phase was to establish a within-subjects laboratory
procedure where drug cues would elicit increased craving responses. The second phase is
designed to establish causation between drug craving and relapse through a self-administration
paradigm. The third phase of the study is designed to use the established procedure to quickly
screen pharmacotherapies for CUDs. A better understanding of the factors that contribute to
continued drug use despite quit attempts is important because such an understanding will help to
develop models and procedures for the evaluation of behavioral and pharmacological therapies
for treatment.

Copyright © Jessica S. Fogel 2015

34

Appendix A.
Cannabis Use Calendar
Have you ever used marijuana? ____Yes ____No
How have you used marijuana? ____ Oral

____ Smoking

Which method was most typical? ______________________________
On the calendar, please circle the days that you used marijuana during the past 4 weeks and
indicate how many times that you used marijuana on that day:
Sun

Mon

Tue

Wed

Thu

Fri

Sat

Sun

Mon

Tue

Wed

Thu

Fri

Sat

Sun

Mon

Tue

Wed

Thu

Fri

Sat

Sun

Mon

Tue

Wed

Thu

Fri

Sat

Sun

Mon

Tue

Wed

Thu

Fri

Sat

How many days in the last year have you used marijuana?
If you have not used marijuana in the past year, when was your last use?

Which of the following best describes your typical use of marijuana:
____ non-medical (e.g., to party, to get high, to relax)?
Identify reason ________________________________________________
____ prescribed by your doctor for a medical purpose?
Identify medical purpose _________________________________________
Has your marijuana use ever been a problem for you or for others? ____Yes ____No
If Yes, explain _________________________________________________________
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Appendix B.
Sign-In Questionnaire
1. How many hours of sleep did you get last night? ___________________
2. Have you used any nicotine products in the last 24 hours?

Yes

No

If you answered “yes”, how many cigarettes have you used in the last 24 hours? ____________
3. Have you had any alcohol in the last 12 hours?

Yes

No

If you answered “yes”, at what time did you have your last drink? ____________
4. Have you had any cannabis in the last 24 hours?

Yes

No

If you answered “yes”, at what time did you last use cannabis? ____________
5. Have you had any caffeinated beverages today?

Yes

No

If you answered “yes”, at what time did you drink your last caffeinated beverage? ___________
6. Have you taken any medications (either prescription or over the counter) or used any illicit
drugs since your last session?
Yes
No
If you answered “yes”, what were the medications and when did you take them?
______________________________________________________________________
7. Have you been ill since your last session?

Yes

No

If you answered “yes”, please explain: _______________________________________
______________________________________________________________________
8. Have you experienced any changes in your usual routine since your last session?
Yes

No

If you answered “yes”, please explain: _______________________________________
______________________________________________________________________
9. If female, when was the start date of your last menstrual cycle? ________________
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Appendix C.
Study Run Sheet
Study day
Type of Cue
Date

Practice

1

2

3

4

5

Setup Materials:
set-up session computer
consent form
urine collection cup
pregnancy test
Check-in procedure
collect keys, watch, phone
smoke break (Y/N)
field sobriety test
BAL
CO
weight
sign in questionnaire
urine screen (to run: negative
for all but THC)
pregnancy screen (to run:
negative)

0:00

%
ppm
lbs.

%
ppm
lbs.

%
ppm
lbs.

%
ppm
lbs.

%
ppm
lbs.

%
ppm
lbs.

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

Assessment 2
(record start time)
BP
HR

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

Assessment 3
(record start time)
BP
HR

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

Assessment 4
(record start time)
BP
HR

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

mmHg
bpm

Assessment 1
(record start time)
BP
HR
Cue Exposure

0:30

1:00
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Check-Out Procedure
return keys, watch,
cell phone
back-up data
Up date earnings sheet

38

Appendix D.
Marijuana Craving Questionnaire – Short Form
Indicate how strongly you agree or disagree with each of the following statements by selecting a
number between 1 (STRONGLY DISAGREE) and 7 (STRONGLY AGREE). The closer your
selection to one end or the other indicates the strength of your agreement or disagreement. If you
don’t agree or disagree with a statement, select the mid-point number 4. Please complete every
item. We are interested in how you are thinking or feeling right now as you are filling out the
questionnaire. When you are done, click the “Next” button.
Please answer the following questions based on how you are feeling RIGHT NOW:
1. Smoking cannabis would be pleasant right now
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
2. I could not easily limit how much cannabis I smoked right now
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
3. Right now, I am making plans to use cannabis
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
4. I would feel more in control of things right now if I could smoke cannabis
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
5. Smoking cannabis would help me sleep better at night
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
6. If I smoked cannabis right now, I would feel less tense
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
7. I would not be able to control how much cannabis I smoked if I had some here
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
8. It would be great to smoke cannabis right now
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
9. I would feel less anxious if I smoked cannabis right now
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
10. I need to smoke cannabis now
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
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11. If I were smoking cannabis right now, I would feel less nervous
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
12. Smoking cannabis would make me content.
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE
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Appendix E.
Visual Analog Scale
A series of questions will be individually presented on the computer screen. Use the mouse to move
the indicator to the place on the line, labeled “Not at all” on the left and “Extremely” on the right,
which best indicates how you feel at the moment, and then click the mouse button. You can change
your answer by repositioning the indicator along the line and clicking again. When you are done,
click the “Next” button.
Please answer the following questions based on how you are feeling RIGHT NOW:
I feel…
Sedated
Stimulated
Nauseated
Shaky or Jittery
Restless
Dizzy
Difficulty Concentrating
Anxious
Nervous
I have a craving for…
Alcohol
Tobacco
Marijuana
Cocaine
Opiates
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Appendix F.
Subject-Rated Physiological Questionnaire
Indicate how aware you were of the following symptoms while handling the objects by selecting
a number between 1 (NOT AT ALL) and 5 (ALL OF THE TIME). The closer your selection to
one end or the other indicates the strength of your awareness. Please complete every item. We are
interested in how you were thinking or feeling during the time you were handling the objects
as you are filling out the questionnaire. When you are done, click the “Next” button.
During the time you were handling the object, how much of the time were you aware of
each? Click on the NEXT button to go to the next statement.
1. Faster heart rate
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
2. Rapid breathing
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
3. Sweating hands
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
4. Heavy feeling in the stomach
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
5. Loud pounding heart
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
6. Tensed muscles
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
7. Cold hands
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
8. Feeling flushed or hot
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
9. Salivating more
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
10. Trembling
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
11. Dry mouth
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME
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University of Michigan

September 2007December 2007

Research Assistant
Department of Cultural and Social Psychology
University of Michigan

ADVISING ACTIVITIES
Undergraduate Students
Tyler Delong

Inna Malyuk, B.A.

Spring 2015
BIO 395: Independent Work in Biology
University of Kentucky College of Arts and Sciences
Summer 2014
University of Kentucky
Summer Training in Alcohol Research
Center for Drug Abuse Research Translation
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PROFESSIONAL ACTIVITIES
Memberships
Joined 2013
College on Problems of Drug Dependence

Awards
2014

2014-2015

Women and Gender Junior Investigator Travel Award
College on Problems of Drug Dependence Annual Meeting
San Juan, Puerto Rico
National Institute on Drug Abuse Predoctoral Training Fellowship
Department of Behavioral Science, University of Kentucky College
of Medicine

RESEARCH & INTELLECTUAL CONTRIBUTIONS
Publications
Peer-Reviewed Original Research in Scientific Journals
4. Fogel JS, Kelly TH, Westgate PM, Lile JA (2014) Sex differences in the subjective effects of
oral Δ9-THC in cannabis users. In submission.
3. Jansen LA, Fogel JS, Brubaker M (2013) Experimental philosophy, clinical intentions, and
evaluative judgment. Cambridge Quarterly Journal of Health Care Ethics, 22: 126-135.
PMID: 23507175.
2. Jansen LA, Appelbaum PS, Klein WK, Weinstein ND, Cook W, Fogel JS, Sulmasy DP (2011)
Unrealistic optimism in early-phase oncology trials. IRB: Ethics and Human Research,
33: 1-8. PMID: 21314034.
1. Jansen LA, Fogel JS (2010) Ascribing intentions in clinical decision-making. Journal of
Medical Ethics, 36: 2-6. PMID: 20026685.
Book Chapters
Lile JA, Fogel JS, Kelly TH (2014) The role of -aminobutyric acid in the interoceptive effects of
oral 9-tetrahydrocannabinol in humans. In: Preedy VR, (ed), The Comprehensive
Handbook of Cannabis Related Pathology.

Abstract Presentations
National/International
14. Fogel JS, Kelly T, Harvanko A, Lile J (2015). Effects of repeated cue exposure on cannabis
craving. Poster presentation. Problems of Drug Dependence 2015: College on Problems
of Drug Dependence 77th Annual Scientific Meeting. Phoenix, Arizona
13. Harvanko AM, Martin CM, Fogel JS, Lile JA, Kelly TH (2015) A comparison of the
behavioral effects of electronic and tobacco cigarettes following 24-hr tobacco
deprivation. Poster presentation. Problems of Drug Dependence 2015: College on
Problems of Drug Dependence 77th Annual Scientific Meeting. Phoenix, Arizona
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12. Harvanko AM, Martin CM, Fogel JS, Lile JA, Kelly TH (2015) The abuse liability of
electronic cigarettes as a function of nicotine dose. Poster presentation. American
Psychological Association 123th Annual Scientific Meeting, Division 28
Psychopharmacology and Substance Abuse Poster Session and NIDA/NIAA/APA
(Divisions 28 and 50) Early Career Investigators Poster Session and Social Hour.
Toronto, Canada
12. Harvanko AM, Martin CM, Fogel JS, Lile JA, Kelly TH (2015) A comparison of the selfreported effects of electronic and conventional cigarettes. Poster presentation. University
of Kentucky Clinical and Translational Research Spring Conference 2015. Lexington,
KY
11. Fogel JS, Kelly T, Charnigo R, Harvanko A, Lile J (2014) Predictors of the response to oral
Δ9-THC in regular cannabis users: Focus on sex differences. Poster presentation.
Problems of Drug Dependence 2014: College on Problems of Drug Dependence 76th
Annual Scientific Meeting. San Juan, Puerto Rico
10. Fogel JS, Kelly T, Charnigo R, Harvanko A, Lile J (2014) Sex differences in subjective and
physiological responses to oral Δ9-THC in regular cannabis users. Poster presentation.
University of Kentucky Clinical and Translational Research Spring Conference 2014.
Lexington, KY
9. Lile J, Kelly T, Stoops W, Fogel JS, Harvanko A, Charnigo R, Hays L (2014) Cannabis selfadministration in the laboratory and use in the natural environment during outpatient
tiagabine maintenance. Poster presentation. Problems of Drug Dependence 2014: College
on Problems of Drug Dependence 76th Annual Scientific Meeting. San Juan, Puerto Rico
8. Harvanko AM, Martin CM, Charnigo RJ, Fogel JS, Lile JA, Kelly TH (2014) Predicting the
effects of d-amphetamine using measures of sensation seeking and impulsivity. Poster
presentation. Problems of Drug Dependence 2014: College on Problems of Drug
Dependence 76th Annual Scientific Meeting. San Juan, Puerto Rico
7. Harvanko AM, Martin CM, Charnigo RJ, Fogel JS, Lile JA, Kelly TH (2014) The relationship
between sensation seeking and impulsivity on d-amphetamine taking behavior. Poster
presentation. University of Kentucky Clinical and Translational Research Spring
Conference 2014. Lexington, KY
6. Kelly TH, Anderson A, Jenkins S, Harvanko A, Martin CA, Fogel JS, Joseph J, Lile JA (2014)
d-Amphetamine effects and monetary incentive delay task performance: an fMRI study.
Poster presentation. Problems of Drug Dependence 2014: College on Problems of Drug
Dependence 76th Annual Scientific Meeting. San Juan, Puerto Rico
5. Sullivan MA, Manubay JM, Vosburg SK, Jones JD, Cooper ZD, Fogel JS, Davidson JW,
Comer SD (2013) Buprenorphine/naloxone for the treatment of prescription opioid abuse
and chronic pain. Poster presentation. Problems of Drug Dependence 2013: College on
Problems of Drug Dependence 75th Annual Scientific Meeting. San Diego, CA
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4. Manubay JM, Davidson JW, Vosburg SK, Jones JD, Cooper ZD, Fogel JS, Comer SD,
Sullivan MA (2013) Sex differences among opioid-abusing chronic pain patients in a
clinical trial. Poster presentation. Problems of Drug Dependence 2013: College on
Problems of Drug Dependence 75th Annual Scientific Meeting. San Diego, CA
3. Mogali S, Askalsky P, Fogel JS, Madera G, Jones JD, Sullivan MA, Manubay JM, Comer SD
(2013) The effects of minocycline on oxycodone-induced responses. Podium
presentation. Experimental Biology 2013. Boston, MA
2. Comer SD, Bisaga A, Jones JD, Mogali S, Manubay JM, Sullivan MA, Vosburg SK, Cooper
ZD, Roux P, Fogel JS, Shiffrin L (2012) Relationship between reactivity to heroinrelated cues, heroin craving, and heroin self-administration in buprenorphine-maintained
heroin abusers. Poster presentation. American College of Neuropsychopharmacology
2012. Hollywood, FL
1. Manubay JM, Vosburg SK, Comer SD, Jones JD, Cooper ZD, Fogel JS, Sullivan MA (2011)
Sex differences in patients with chronic pain and prescription opioid abuse during
buprenorphine/naloxone maintenance. Poster presentation. Problems of Drug
Dependence 2011: College on Problems of Drug Dependence 73rd Annual Scientific
Meeting. Hollywood, FL
Sponsored Research Funding
Principal Investigator
Active
Title:
Effects of Environmental Cues on Cannabis Craving
PI:
Jessica Fogel (faculty mentor: Joshua Lile, Ph.D.)
Source:
Department of Behavioral Science, University of Kentucky College of Medicine
Duration:
02/12/14-06/30/14
Total Award: $3,120
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